$8.2M isn't bad for sales in only a few foreign counties
Sales of $8.2M, or 5M euros, isn't a bad showing for Lemtrada in the just completed Q1:F'14, especially considering the few foreign countries where it has been launched, and for many for only a partial period of time.
You are right, it is not bad, except that the clock is ticking on the milestone and it seems highly unlike that the $400mm will be met. That means that the next "bet" is the big one for $1.8B...which is way out there. This is dead money for a long, long time.
(Reuters) - Sanofi said it plans to resubmit its application for its Lemtrada drug for the treatment of relapsing forms of multiple sclerosis following "constructive discussions" with the U.S. Food and Drug Administration.
Alemtuzumab has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The FDA's Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Under Fast Track designation, alemtuzumab for MS is eligible for Priority Review.
The Scottish Medicines Consortium is due to consider alemtuzumab in May.